Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults

NCT04445389 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

60

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor decided to change the investigational product for a strategic reason.

Conditions

SARS-CoV-2

Interventions

DRUG: GX-19
DRUG: Saline

Sponsor

Genexine, Inc.